Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase

被引：40

作者：

Argov, Z. ^{[1
]}

Mckee, D.

Agus, S.

Brawer, S.

Shlomowitz, N.

Ben Yoseph, O.

Soreq, H.

Sussman, J. D.

机构：

[1] Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel

[2] Hebrew Univ Jerusalem, Hebrew Univ Med Ctr, Jerusalem, Israel

[3] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Jerusalem, Israel

[4] Hebrew Univ Jerusalem, Israel Ctr Neuronal Computat, Jerusalem, Israel

[5] Ester Neurosci Ltd, Herzliyya, Israel

[6] Hope Hosp, Greater Manchester Neurosci Ctr, Dept Neurol, Salford M6 8HD, Lancs, England

来源：

NEUROLOGY | 2007年 / 69卷 / 07期

关键词：

D O I：

10.1212/01.wnl.0000267884.39468.7a

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：699 / 700

页数：5

共 6 条

[1] Antisense therapeutics [J].

Agrawal, S ;

Zhao, QY .

CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :519-528

[2] Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity [J].

Bedlack, RS ;

Simel, DL ;

Bosworth, H ;

Samsa, G ;

Tucker-Lipscomb, B ;

Sanders, DB .

NEUROLOGY, 2005, 64 (11) :1968-1970

[3] The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis [J].

Brenner, T ;

Hamra-Amitay, Y ;

Evron, T ;

Boneva, N ;

Seidman, S ;

Soreq, H .

FASEB JOURNAL, 2003, 17 (02) :214-222

[4] Myasthenia gravis - Recommendations for clinical research standards [J].

Jaretzki, A ;

Barohn, RJ ;

Ernstoff, RM ;

Kaminski, HJ ;

Keesey, JC ;

Penn, AS ;

Sanders, DB .

NEUROLOGY, 2000, 55 (01) :16-23

[5]

Soreq H, 2000, ISRAEL MED ASSOC J, V2, P81

[6] Making sense of antisense [J].

Vidal, L ;

Blagden, S ;

Attard, G ;

de Bono, J .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (18) :2812-2818

← 1 →